132 related articles for article (PubMed ID: 16227427)
1. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents.
Montagna GL; Malesci D; Buono R; Valentini G
Ann Rheum Dis; 2005 Nov; 64(11):1667. PubMed ID: 16227427
[No Abstract] [Full Text] [Related]
2. Erythema multiforme with tumour necrosis factor inhibitors: a class effect?
Kain T; MacGregor D; Buchanan RR; de Jager JP; Schachna L
Ann Rheum Dis; 2008 Jun; 67(6):899-900. PubMed ID: 18474663
[No Abstract] [Full Text] [Related]
3. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
[No Abstract] [Full Text] [Related]
4. Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?
Hernández MV; Ruiz-Esquide V; Gómez-Caballero ME; Gómez-Puerta JA; Cañete JD; Sanmartí R
Rheumatology (Oxford); 2011 Aug; 50(8):1523-5. PubMed ID: 21593064
[No Abstract] [Full Text] [Related]
5. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
[TBL] [Abstract][Full Text] [Related]
6. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers.
Richez C; Blanco P; Lagueny A; Schaeverbeke T; Dehais J
Neurology; 2005 Apr; 64(8):1468-70. PubMed ID: 15851749
[TBL] [Abstract][Full Text] [Related]
7. Tuberculosis and granuloma formation in patients receiving anti-TNF therapy.
Iliopoulos A; Psathakis K; Aslanidis S; Skagias L; Sfikakis PP
Int J Tuberc Lung Dis; 2006 May; 10(5):588-90. PubMed ID: 16704045
[TBL] [Abstract][Full Text] [Related]
8. Tuberculous peritonitis.
Finlay DG; Szauter K; Raju GS; Snyder N
Am J Gastroenterol; 2005 Jul; 100(7):1624-5. PubMed ID: 15984997
[No Abstract] [Full Text] [Related]
9. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
Gaspersic N; Sersa I; Jevtic V; Tomsic M; Praprotnik S
Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
[No Abstract] [Full Text] [Related]
10. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
Capkin E; Karkucak M; Yayli S; Aydin Çapkin A; Tosun M
J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
[No Abstract] [Full Text] [Related]
11. Localized Cutaneous Leishmaniasis due to Leishmania infantum in a Patient Treated with Infliximab.
Hakimi S; Rivière S; Del Giudice P; Dereure J; Le Quellec A
Dermatology; 2010; 220(1):63-5. PubMed ID: 19907139
[TBL] [Abstract][Full Text] [Related]
12. Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab.
Paschou S; Voulgari PV; Vrabie IG; Saougou IG; Drosos AA
J Rheumatol; 2009 Feb; 36(2):351-4. PubMed ID: 19040305
[TBL] [Abstract][Full Text] [Related]
13. Sézary syndrome in a patient receiving infliximab for ankylosing spondylitis.
Dauendorffer JN; Rivet J; Allard A; Bachelez H
Br J Dermatol; 2007 Apr; 156(4):742-3. PubMed ID: 17263820
[TBL] [Abstract][Full Text] [Related]
14. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
[No Abstract] [Full Text] [Related]
15. Guillain-Barré syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature.
Silburn S; McIvor E; McEntegart A; Wilson H
Ann Rheum Dis; 2008 Apr; 67(4):575-6. PubMed ID: 18349168
[No Abstract] [Full Text] [Related]
16. A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines.
Temel M; Atagündüz P; Direskeneli H
Ann Rheum Dis; 2005 Sep; 64(9):1383-4. PubMed ID: 16100352
[No Abstract] [Full Text] [Related]
17. Cardiopulmonary arrest after severe anaphylactic reaction to second infusion of infliximab in a patient with ankylosing spondylitis.
Miki H; Okamoto A; Ishigaki K; Sasaki O; Sumitomo S; Fujio K; Yamamoto K
J Rheumatol; 2011 Jun; 38(6):1220. PubMed ID: 21632692
[No Abstract] [Full Text] [Related]
18. Dermatitis herpetiformis in a patient receiving infliximab for ankylosing spondylitis.
Marakli SS; Uzun S; Ozbek S; Tuncer I
Eur J Dermatol; 2008; 18(1):88-9. PubMed ID: 18086603
[No Abstract] [Full Text] [Related]
19. Survival and safety of treatment with infliximab in the elderly population.
Chevillotte-Maillard H; Ornetti P; Mistrih R; Sidot C; Dupuis J; Dellas JA; Tavernier C; Maillefert JF
Rheumatology (Oxford); 2005 May; 44(5):695-6. PubMed ID: 15705631
[No Abstract] [Full Text] [Related]
20. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J
Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
